Lower GI Course (Rectal Cancer/Anal Cancer) – Provisional program Online Course, tentatively scheduled March 25-26, 2021

| Rectal Cancer (RC): Prerecorded Lecture Session 1: Introduct | ion: Standard of Care | |
|--|-----------------------|--|
| Topic | Speaker | |
| MRI staging for early, intermediate and advanced rectal cancer | R. Beets-Tan | |
| What is considered standard of care for radiotherapy (short-course RT, chemoradiation)? | C. Marijnen | |
| What is considered standard of care for concurrent and induction/adjuvant chemotherapy, including TNT? | R. Glynne-Jones | |
| Surgical concepts after neoadjuvant treatment: TME, local excision, W&W | G. Beets | |
| RC: Prerecorded Lecture Session 2: RT-Dose/Constraints/RT- | Technique | |
| Dose-response, dose-volume effects and dose constraints for tumour and normal tissue | A. Appelt | |
| IMRT/VMAT/SIB/IGRT/Adaptive RT | K. Haustermans | |
| RC: Prerecorded Lecture Session 3: Delineation | | |
| International consensus guideline on CTV delineation | MA Gambacorta | |
| RC: Prerecorded Lecture Session 4: Future perspectives | | |
| Newer chemotherapy and targeted agents combined with RT/CRT | C. Rödel | |
| Ongoing and planned clinical trials on combined modality treatment for rectal cancer | E. Fokas | |

| RC: Interactive Q&A Session | | | |
|-----------------------------|--|---|--|
| 1,5-2 h | Discussion of Falcon Contouring of participants | MA Gambacorta/K. Haustermans participants | |
| 1,5-2 h | Interactive: Organ preservation and TNT: Where do we stand? | All teachers/participants | |
| 1,5-2 h | Tumor board: Case presentations (by participants) and questions on diagnosis and treatment: Bring your own cases and discuss with experts and other participants | All teacher/participants | |
| | n.n. | | |

| Anal Car | ncer: Prerecorded Lecture Session 1: Introduction: St | andard of Care |
|----------|--|-----------------|
| | Topic | Speaker |
| | Imaging-based staging and response evaluation/prediction (Role of MRI, PET-CT) | R. Beets-Tan |
| | What is considered standard of care for radiotherapy? | C. Marijnen |
| | What is considered standard of care for concurrent chemotherapy? Role of induction- and adjuvant chemotherapy? | R. Glynne-Jones |
| | Role of salvage surgery for non-responders and locoregional recurrence | G. Beets |
| AC: Prer | AC: Prerecorded Lecture Session 2: RT-Dose/Constraints/RT-Technique | |
| | Treatment planning: state of the art and challenges (IMRT/SIB/adaptive RT) | A. Appelt |
| AC: Prer | ecorded Lecture Session 3: Delineation | |
| | Atlas and contouring guidelines for anal cancer radiotherapy | MA Gambacorta |
| AC: Prer | ecorded Lecture Session 4: Future perspectives | |
| | Prognostic and predictive biomarkers | E. Fokas |
| | Ongoing and planned clinical trials on combined modality treatment for anal cancer | C. Rödel |

| AC: Interactive Q&A Session | | | | |
|-----------------------------|--|---|--|--|
| 1,5-2 h | Discussion of Falcon Contouring of participants | MA Gambacorta/K. Haustermans participants | | |
| 1,5-2h | Interactive: Hot topics in AC: increasing incidence, HPV biology, paradigm for virus-induced cancer, role of immunotherapy | All teacher/participants | | |
| 1,5-2 h | Tumor board: Discussion of special cases and take-home messages | All teacher/participants | | |